A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Khmelnytskyi Regional Oncology Center, Khmelnytsky

Sumy Regional Clinical Oncology Center, Sumy

Dnipropetrovsk State Medical Academy, Dnipropetrovsk

Kharkiv State Public Healthcare Institution: Kharkiv Regional Clinical Oncology Center, Kharkiv

Ivano-Frankovsk State Medical University; Oncology Department Clinical Facility, Ivano-Frankivsk

Public Treatment and Prophylaxis Institution; Donetsk Regional Antitumor Center, Donetsk

Zakarpattia Regional Clinical Oncology Center, Uzhhorod

Institution of the Russian Academy of Medical Sciences Russian Oncological Research Center, Moscow

Non-Government Medical Institution: Central Clinical Hospital #2, Moscow

Regional Clinical Oncology Center, Yaroslavl

Arkhangelsk Regional Clinical Oncology Center, Arkhangelsk

St. Petersburg Medical University, Saint Petersburg

City Clinical Oncology Center, Saint Petersburg

State Healthcare Institution: Bryansk Regional Oncology Center, Bryansk

Kursk Regional Oncology Center, Kursk

Stavropol Regional Clinical Oncology Center, Stavropol

State Medical Institution: Pyatigorsk Oncological Center, Pyatigorsk

Tambov Regional Oncology Center, Tambov

State Medical Institution Republic Clinical Oncological Center under the Healthcare Ministry of Tatarstan Republic, Kazan'

State Medical Institution Republican Oncology Center, Saransk

Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk

State Healthcare Institution of Nizhny Novgorod Regiona Nizhny Novgorod Oncology Center, Nizhny Novgorod

City Clinical Hospital #1, Novosibirsk

Primorsky Regional Oncology Center, Vladivostok

Kyiv City Oncology Hospital, Kyiv